Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis

Authors:

Abstract
Ruxolitinib, a Janus kinase 1 and 2 (JAK1/2) inhibitor, is the only approved drug for the treatment of intermediate- or high-risk myelofibrosis.[1] In the phase 3 registration trials, ruxolitinib d...

This publication has 10 references indexed in Scilit: